{"id":1393,"date":"2019-04-17T14:44:00","date_gmt":"2019-04-17T14:44:00","guid":{"rendered":"https:\/\/blogs.bmj.com\/spcare\/?p=1393"},"modified":"2019-04-17T14:44:00","modified_gmt":"2019-04-17T14:44:00","slug":"news-and-updates-from-www-palliativedrugs-com-106","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/spcare\/2019\/04\/17\/news-and-updates-from-www-palliativedrugs-com-106\/","title":{"rendered":"News and updates from www.palliativedrugs.com"},"content":{"rendered":"

Selected items from the News and Latest Additions sections of www.palliativedrugs.com<\/a>, the world\u2019s leading palliative care website with over 30,000 members from 169 Countries.<\/strong><\/em><\/p>\n

SAFETY UPDATES<\/h3>\n

CME T34 syringe pumps now require foam pads to be added to the battery compartment<\/b><\/p>\n

All Caesarea Medical Electronics (CME) T34 Ambulatory syringe pumps in the UK now need a foam pad to be added to the battery compartment to ensure the battery rests securely against the contacts. Kits should be ordered from CME to do this.<\/span><\/p>\n

This information is in the latest CME field safety notice (FSN2018-001_Updated) and follows the previous alerts in <\/span>March<\/span><\/a> and <\/span>September<\/span><\/a> 2018, highlighting the possible loss of function due to inadequate battery connection. For more information, click <\/span>here<\/span><\/a>.<\/span><\/p>\n

 <\/p>\n

Risk of severe and fatal burns with emollients<\/b><\/p>\n

Warnings about the risk of severe and fatal burns are being extended to all paraffin-based emollients regardless of the paraffin concentration. The Medicines and Healthcare products Regulatory Agency (MHRA) state that the emollients themselves are not flammable, however they act as an accelerant when there is a build-up of emollient on fabric, e.g. clothing, bedding or dressings. Patients should be instructed not to smoke or go near naked flames. For more information, click <\/span>here<\/span><\/a>.<\/span><\/p>\n

 <\/p>\n

MHRA new restrictions and precautions for fluoroquinolone antibiotics<\/b><\/p>\n

New restrictions and precautions for use of fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin) are being introduced by the MHRA following very rare reports of potentially irreversible undesirable effects affecting the musculoskeletal and nervous systems, e.g. tendinitis, muscle pain, joint pain, peripheral neuropathy. Information for health professionals includes:<\/span><\/p>\n